Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer p...
Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...
Bayer (OTC:BAYRY) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.24 by 45.83 pe...
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety c...
Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwin...
Bayer (OTC:BAYRY) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.38 by 71.05 pe...
Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive pa...
Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, wi...
Bayer (OTC:BAYRY) is looking for FY2025 Adj EPS of $4.80-$5.33 vs $4.62 analyst estimate. sees sales of $48.250 billion-$50.239...
